文献速递免疫规划慢病防控与筛查卫生政策与健康促进

提高重组带状疱疹疫苗覆盖率对50-59岁成人带状疱疹负担的潜在影响

The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
PubMed 文献 · Vaccine · 2023-08-03

本研究采用多队列马尔可夫模型,比较美国50-59岁成人2020年实际重组带状疱疹疫苗(RZV)覆盖率与更高覆盖率情景下的终身结局。将覆盖率从7.3%提高至14.6%可避免额外504468例带状疱疹、42077例带状疱疹后神经痛和56247例其他并发症,并节省社会成本。

要点

  • 美国50-59岁成人RZV覆盖率从7.3%升至14.6%可避免504468例带状疱疹。
  • 该覆盖率提升还可避免42077例带状疱疹后神经痛和56247例其他并发症。
  • 覆盖率提升带来疫苗接种成本增加,但社会角度净节省143059299美元。

核心结论

  • 美国50-59岁成人适度提高RZV覆盖率可降低带状疱疹相关临床负担,并可能带来社会成本节省。

研究设计与样本

  • 多队列马尔可夫模型,基于2020年美国人口普查纳入42756488人队列,比较2020年实际RZV覆盖率与假设更高覆盖率情景,采用终身时间 horizon。

主要发现

  • 覆盖率从7.3%提高至14.6%可避免额外504468例带状疱疹、42077例带状疱疹后神经痛和56247例其他带状疱疹相关并发症。
  • 覆盖率提高导致疫苗接种相关成本增加1172411566美元,但避免的病例和并发症带来直接成本节省721973386美元和间接成本节省593497480美元。
  • 社会角度获得5230个贴现质量调整生命年(QALY)和143059299美元的成本节省。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recombinant zoster vaccine (RZV) is recommended in the US for prevention of herpes zoster (HZ) in adults aged ≥50 years. Vaccination rates remain suboptimal for adults 50-59 years compared with adults ≥50 years overall. The objective of this study was to model changes in outcomes associated with improved RZV vaccination coverage in US adults 50-59 years. METHODS: A multicohort Markov model compared a scenario using real-world vaccination coverage for US adults 50-59 years in 2020 versus scenarios assuming higher coverage. Outcomes, based on a lifetime horizon, included HZ cases and complications avoided, quality-adjusted life-years (QALY), and costs. Model inputs included HZ epidemiology, RZV vaccine efficacy, coverage, adverse events, and costs, based on published literature and US sources. Some inputs were updated from previous models, including real-world estimates of RZV coverage, series completion, and reflecting longer-term data on waning of vaccine efficacy. The model utilized a cohort size of 42,756,488 individuals based on the 2020 US population census. RESULTS: The model projected that increasing RZV coverage in adults 50-59 years from 7.3 % to 14.6 % (to coverage for adults 60-64 years in 2020) would avoid an additional 504,468 HZ cases, 42,077 postherpetic neuralgia cases, and 56,247 cases of other HZ-associated complications. The increase in vaccine coverage would result in higher vaccination-related costs of $1,172,411,566, but the avoided HZ cases and complications would be expected to result in direct cost savings of $721,973,386 and indirect cost savings of $593,497,480 from avoided productivity loss. Overall, a gain of 5,230 discounted QALYs and cost savings of $143,059,299 from a societal perspective would be realized. CONCLUSION: Modestly higher RZV coverage in US adults 50-59 years could reduce the clinical burden associated with HZ and may result in societal cost savings. These findings demonstrate the potential value of increasing RZV vaccination in this population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Singer D, Salem A, Stempniewicz N, et al. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years. Vaccine. 2023. PMID: 37541822. doi:10.1016/j.vaccine.2023.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。